Breast Cancer Information Site

Postoperative chemotherapy for all patients with breast cancer are not effective, semi-breast cancer causes over-treatment for all! 80% of all breast cancer patients undergo chemotherapy after surgery, but from the head point of view, and a half is not sensitive to chemotherapy patients, for them, a side effect of chemotherapy is far in the therapeutic effect. The latest view is that the international community to neo-adjuvant chemotherapy, or chemotherapy before surgery on the one hand, can determine whether patients with chemotherapy-sensitive. Effective, as with drugs do “skin test” the same; the other hand, preoperative chemotherapy may the majority of primary breast cancer significantly reduced the volume and improve breast-conserving opportunities.

Postoperative chemotherapy or detrimental to blindly

In breast cancer patients over-treatment, excessive chemotherapy are more common. In fact, some patients more sensitive to chemotherapy, there is one with obvious effects in some patients but there are not very sensitive to chemotherapy after the cancer has not decreased significantly. In the kinds of cases, the therapeutic effect is far smaller than the side effects of chemotherapy will only damage the health blindly. Ye Changsheng said that breast cancer is now the most common postoperative chemotherapy, 80% of breast cancer patients are treated this way. However, from the clinical point of view, half of which are not sensitive to chemotherapy patients, they blindly made one after another course of treatment, no significant improvement in not only the condition, but condition worse.

How to determine whether the sensitivity to chemotherapy in patients with effective, how to make chemotherapy, patients are not sensitive to avoid the worse? In recent years, the international medical community has tried to find another way, this was a new adjuvant chemotherapy. Postoperative chemotherapy in general are carried out, while the neo-adjuvant chemotherapy before surgery is carried out. The introduction of new adjuvant chemotherapy, which can effectively determine whether patients with chemotherapy-sensitive, which should determine whether postoperative chemotherapy, and how it should be chemotherapy. In addition, preoperative chemotherapy can enable the majority of primary breast cancer significantly reduced the volume of advanced breast cancer can increase the removal rate of early breast cancer can improve conserving opportunities.

Adjuvant therapy for breast cancer “new concept”

Adjuvant therapy for breast cancer, the medical profession has a lot of “new concept”, including:

1. Individualized adjuvant therapy. Adjuvant endocrine therapy for adjuvant treatment is the individual the best example. Many years of clinical practice has confirmed that hormone receptor-positive breast cancer patients using this therapy can achieve better effect.

2. Intensive chemotherapy. Generally speaking, each course of conventional chemotherapy to be administered 3 weeks, but the latest study found that every 2 weeks dose administration compared with conventional three weeks of tumor cell-killing effect the most, and the tumor cells is not easy to resume normal growth. In 2005 and 2006 edition of “American NCCN breast cancer treatment guidelines” in both the dose-intensive programs as a standard adjuvant treatment for early breast cancer one of the options.

3. Drug regulation ovary. A series of clinical trial results suggest that pairs of pre-menopausal hormone receptor-positive cases of high-risk relapse of ovarian resection can improve survival. However, due to surgery on the patient’s psychological side effects, as well as the impact of an increasing number of patients abroad use drugs to regulate ovarian function. Commonly used drugs are pituitary luteinizing hormone releasing hormone analogue goserelin, compared with surgery and chemotherapy, its better efficacy and lower toxicity.

4. Targeted therapy. Targeted therapy is the use of tumor cells can express, but little or no expression in normal cells the product of specific genes to form a relative or absolute target, to maximize anti-tumor cells, but little damage to normal cells. Molecular targeted therapy of breast cancer in recent years, one of the most active areas of research, some of them have successfully applied to molecular-targeted drugs to enter clinical or clinical trials, of which the most successful is the trastuzumab used in early breast cancer adjuvant therapy.